Last year, Parexel watched its stock price drop after reporting an unexpected decline in net new business, but that was a mere blip and not the beginnings of an alarming trend, the CRO said, boosting its expectations for the next quarter.
Another year, another merger for BioClinica as the once-public CRO prepares to combine its operations with CCBR-Synarc, a specialized clinical services outfit.
San Francisco clinical trial software outfit goBalto has made its first big international push, opening outposts in Singapore and the U.K.
Montreal's JSS Medical Research has acquired competitor Integrated Research Inc., completing a deal the CRO says makes it the largest Canadian-owned contract researcher.
Contract researcher Avillion launched last year with a novel approach to contract drug development, planning to team up with Big Pharmas on late-stage assets and take drugs to the finish line in exchange for a cut of the proceeds. Now the London company has reeled in a big-name partner in Pfizer, signing on to run a Phase III study of the cancer-fighting Bosulif.
Italy's CROS NT has bought out MDSL International, absorbing the U.K. company's expertise in clinical data management, statistics and other biometrics services.
Theorem Clinical Research is looking to up its game in cardiac trials, teaming up with BioTelemetry for access to high-tech core labs and a bigger share of the market.
Global CRO Quintiles has struck up a deal with the Medical Affairs Company, a medical liason contractor, and the two companies plan to pool their powers in drug and device commercialization.
For CROs and their sponsors, secrecy doesn't do anyone any good, a group of experts tells Genetic Engineering News, and building a strong relationship depends on transparency, shared goals and an upfront understanding of what's to be delivered.
After years of allowing loosely regulated clinical trials that often put patients at risk, the Indian government has taken a 180-degree turn, now further strengthening its rules by mandating that ethics committees must be registered and accredited before a study can begin.
Analysts have high hopes for the world's largest CROs, which continue to expand their market shares in an ever-consolodating industry, but Massachusetts giant Parexel broke from the pack last quarter with a costly stumble. Now, as the company gears up for another earnings release, investors will be watching closely to see whether CEO Josef von Rickenbach has corrected its course.
Kidney dialysis mainstay DaVita HealthCare is working to boost the profile of its in-house CRO, recruiting a few experts to expand its early-phase capabilities.
Pharma giant Sanofi is jumping on the clinical trial transparency bandwagon, agreeing to share data with researchers public and private, but the French drugmaker's plan stops short of the sweeping initiatives favored by some of its rivals.
The U.K.'s Cyprotex has picked up competitor CeeTox in a deal worth up to $5.1 million, boosting its offerings in in vitro testing and expanding into cosmetics and personal care.
Come January, Italy's CROS NT will have a new CEO, as Andrew MacGarvey will take the reins from longtime chief Paolo Morelli.
Preclinical CRO Charles River Laboratories is shuffling its high offices in an effort to better focus on efficiency, uniting its business units to slash spending and speed up growth.
Global pharma giant Bayer has inked a three-year deal with the University of Texas' MD Anderson Cancer Center to run clinical trials, matching its investigators with patient-serving oncologists in a deep-seated collaboration.
Belgium's Genae has expanded its European footprint, cutting the ribbon on a Swiss office with its eye on a bigger share of the market for medical device development.
U.K. CRO Quotient Clinical is now the property of private equity outfit Bridgepoint Development Capital, joining the crowd of pharma contractors signing up to be acquired in a fast-consolidating industry.
Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.